MREO vs. LXRX, AMRN, MRSN, BMEA, RVNC, CRBP, ESPR, NATR, PEPG, and ADCT
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Mersana Therapeutics (MRSN), Biomea Fusion (BMEA), Revance Therapeutics (RVNC), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), Nature's Sunshine Products (NATR), PepGen (PEPG), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical preparations" industry.
Lexicon Pharmaceuticals (NASDAQ:LXRX) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Mereo BioPharma Group has higher revenue and earnings than Lexicon Pharmaceuticals.
Mereo BioPharma Group has a net margin of 0.00% compared to Mereo BioPharma Group's net margin of -8,311.12%. Lexicon Pharmaceuticals' return on equity of 0.00% beat Mereo BioPharma Group's return on equity.
In the previous week, Lexicon Pharmaceuticals had 9 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 10 mentions for Lexicon Pharmaceuticals and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.59 beat Lexicon Pharmaceuticals' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.
Lexicon Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Lexicon Pharmaceuticals received 433 more outperform votes than Mereo BioPharma Group when rated by MarketBeat users. However, 71.11% of users gave Mereo BioPharma Group an outperform vote while only 64.58% of users gave Lexicon Pharmaceuticals an outperform vote.
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 4.5% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Lexicon Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 179.33%. Mereo BioPharma Group has a consensus target price of $6.50, suggesting a potential upside of 114.52%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Mereo BioPharma Group.
Summary
Lexicon Pharmaceuticals beats Mereo BioPharma Group on 8 of the 15 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
